7266 – MicroRNA Mimics for the Treatment of Cardiometabolic Diseases

Background & Unmet Need:

Impaired cholesterol and fat metabolism contribute to many cardiometabolic diseases, including obesity, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis.
Numerous regulatory factors have been found to modulate metabolic regulation of lipids, and are thus attractive therapeutic targets
The sterol regulatory element-binding protein-2 (SREBP-2) directed transcription of low-density lipoprotein (LDL) receptor is essential for the removal of atherogenic LDL from circulation
Post-translationally, LDLR-mediated cholesterol uptake is limited by SREBP-2- and LXR-induced counter mechanisms
However, coordinated cellular mechanisms that restrict or prevent LDLR from degradation upon transcription remain uncharacterized
Unmet Need: Improved understanding of LDLR regulation to inform the development of novel treatments


Technology Overview:

The Technology: miRNA-33a-3p mimics that lower LDL and reduce hepatic steatosis for the treatment of cardiometabolic diseases such as NAFLD
The Discovery: miRNA-33a, encoded within the SREBP-2 gene, acts to promote LDLR expression and LDL-uptake through direct targeting of PCSK9, IDOL, and ANGPTL3.
PoC Data: Liver-targeted delivery of miRNA-33a-3p mimics into mouse models of diet-induced obesity resulted in reduced hepatic and circulating PCSK9 levels as well as serum ANGPTL3 levels
miRNA-33a-3p mimics significantly lower LDL, and ameliorate hepatic steatosis while increasing HDL
miRNA-33a-3p mimics, therefore, represent alternative therapeutic inhibitors of PCSK9, ANGPTL3, and LDL-cholesterol for reducing hypercholesterolemia and steatohepatitis


Technology Applications:

Treatment and prevention of cardiometabolic diseases and NAFLD/NASH
Reduction of hypercholesterolemia and hypertriglyceridemia in patients with atherosclerosis and insufficient response to statins and dietary changes alone


Technology Advantages:

miRNAs can regulate multiple genes in the same biological process with as individual ~22 nucleotide transcripts
miRNAs can be administered in a tissue-targeted manner to enhance specificity and efficacy while minimizing side effects
miRNA-33a-3p successfully reduced LDL-cholesterol and hepatic steatosis in a mouse model of obesity


Patents:

Provisional Filed

Website:

https://cornell.flintbox.com/technologies/55F9AD7CF41C4F78B749D62800F1B159

Contact Information:

Name : Lukasz Kowalik

Title :

Department :

Email: lk534@cornell.edu

Phone: 646-962-7052

Address :